Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

BACKGROUND: Immune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge after irAEs, and evidence suggests that rechalle...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Siddiqui, Bilal A, Gheeya, Jinesh S, Goswamy, Rohit, Bathala, Tharakeswara K, Surasi, Devaki Shilpa, Gao, Jianjun, Shah, Amishi, Campbell, Matthew T, Msaouel, Pavlos, Goswami, Sangeeta, Wang, Jennifer, Zurita, Amado J, Jonasch, Eric, Corn, Paul G, Aparicio, Ana M, Siefker-Radtke, Arlene O, Sharma, Padmanee, Subudhi, Sumit K, Tannir, Nizar
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323401/
https://ncbi.nlm.nih.gov/pubmed/34326169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002850
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados